Unexpected insights for anti-EGFR cancer therapy
Philippe Depeille, Robert S. Warren and Jeroen P. Roose
Colorectal cancer (CRC) is a major cause of morbidity and mortality. It accounts for over 9% of all malignancies, making it the third most common cancer worldwide and second most common cause of death in the developed world. Treatment of metastatic colorectal cancer (mCRC) is largely palliative, making potentially curative therapy via molecular inhibition of specific cellular targets in CRC a highly sought-after goal.